A Patients Perspective: HCV Viekira Pak
By: Marcus Hopkins, Blogger
In January of this year, the AIDS Crisis Task Force (Task Force) and AbbVie
reached a landmark pricing agreement that offers their new Hepatitis C (HCV)
treatment regimen, Viekira Pak, at a significantly lower cost for state and
territory AIDS Drugs Assistance Programs (ADAPs). For last months research
question for the HIV/HCV Co-Infection Watch Report, I asked every ADAP Director
and Coordinator if this pricing agreement had caused their individual states
to consider adding the regimen to their respective formularies.
I walked away from that first month of research with two observations:
Despite the pricing agreement, it is unlikely that a plurality of states
will be adding Viekira Pak.
The communication process between researchers and Federally funded healthcare
programs needs serious improvement.
CLICK HERE to read, A Patients Perspective: HCV Viekira
Black Market HIV/AIDS Drugs in the News, 2006 -
The Partnership for Safe Medicines
The Community Access National Network (CANN) today announced that it is teaming
up with the Partnership for Safe Medicines (PSM) to better educate patients
about the risks of counterfeit or black market HIV/AIDS medicines. Since
2006, eighty-two (82) individuals have been charged with selling adulterated,
unapproved or black market medications prescribed for HIV or AIDS patients.
HERE to download, "Black Market HIV/AIDS Drugs in the News, 2006 - 2013"